Announcements Trials
Browse Landscape

Phase

Phase 2 8Phase 1/2 2Phase 1 2

Status

Completed 2

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Plasma cell 2

Conditions

Ovarian Neoplasms 11Multiple Myeloma 10Fallopian Tube Neoplasms 7Carcinoma, Ovarian Epithelial 6Breast Neoplasms 6Neoplasms, Plasma Cell 3Sarcoma 2Recurrence 2Prostatic Neoplasms 2Lymphoma 2Breast Neoplasms, Male 2Waldenstrom Macroglobulinemia 1Small Cell Lung Carcinoma 1Sezary Syndrome 1Sarcoma, Synovial 1Sarcoma, Ewing 1Rhabdomyosarcoma 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Patient Participation 1Pancreatic Neoplasms 1Ovarian Cancer Recurrent 1Osteosarcoma 1Neurofibrosarcoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Primary Effusion 1Lymphoma, Non-Hodgkin 1Lymphoma, Mantle-Cell 1Lymphoma, Large-Cell, Immunoblastic 1

Interventions

Dexamethasone 33Cyclophosphamide 31fludarabine 19venetoclax 18Lenalidomide 16Bortezomib 16Cytarabine 13pembrolizumab 12Calcium Dobesilate 12Carboplatin 11fludarabine phosphate 10Rituximab 10pomalidomide 9Gemcitabine 9Nivolumab 8Azacitidine 7daratumumab 6carfilzomib 6blinatumomab 6Decitabine 6Bendamustine Hydrochloride 6selinexor 5obinutuzumab 5ibrutinib 5Vincristine 5Temozolomide 5Methotrexate 5Etoposide 5Cisplatin 5tafasitamab 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Recurrence × liposomal doxorubicin × Clear all
NCT02206425 2023-10-31

Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

Oncotherapeutics

Phase 1/2 Completed
45 enrolled
Plasma cell

Multiple Myeloma, Recurrence

NCT02186834 2023-01-04

Selinexor (KPT-330) and Liposomal Doxorubicin For Relapsed and Refractory Multiple Myeloma

H. Lee Moffitt Cancer Center and Research Institute

Phase 1/2 Completed
28 enrolled 10 charts
Plasma cell

Multiple Myeloma, Recurrence, Neoplasms, Plasma Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡